AI assistant
Sending…
GALECTIN THERAPEUTICS INC — Director's Dealing 2019
Jun 3, 2019
33422_dirs_2019-06-03_ae04e80a-5633-45bd-8fa8-e9eb585c8c93.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2019-05-31
Reporting Person: OMENN GILBERT S (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-05-31 | Common Stock | P | 18578 | $4.28 | Acquired | 66769 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-05-31 | Common Stock Purchase Warrant (right to buy) | $7.00 | P | 61929 | Acquired | 2026-05-31 | Common stock (4644) | Direct |
Footnotes
F1: Each warrant is exerciseable for 0.075 shares of Common Stock of the Company.
More from GALECTIN THERAPEUTICS INC
Regulatory Filings
2026
May 15
Interim / Quarterly Report
2026
May 15
Capital/Financing Update
2026
Mar 31
Earnings Release
2026
Mar 31
Annual Report
2026
Mar 31
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 17
Board/Management Information
2026
Mar 17
Director's Dealing
2026
Feb 9
Board/Management Information
2026
Jan 21